4-[(甲基氨基)甲基]-1,2-苯二酚氢溴酸盐(1:1) | 1025423-95-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-[(甲基氨基)甲基]-1,2-苯二酚氢溴酸盐(1:1)
• 中文别名: 4-[(甲氨基)甲基]邻苯二酚氢溴酸盐
• 英文名称: 4-[(methylamino)methyl]benzene-1,2-diol hydrobromide
• 英文别名: 4-[(Methylamino)methyl]pyrocatechol Hydrobromide；4-(methylaminomethyl)benzene-1,2-diol;hydrobromide
• CAS: 1025423-95-3
• 化学式: BrH*C₈H₁₁NO₂
• 分子量: 234.093
• InChiKey: PRTZQGUEQQHXPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52.5
• 氢给体数：
  4
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-[(甲基氨基)甲基]-1,2-苯二酚氢溴酸盐(1:1) 、 2-(4-氯苯基)乙基 异硫代氰酸酯 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以64%的产率得到1-[2-(4-氯苯基)乙基]-3-[(3,4-二羟基苯基)甲基]-3-甲基硫脲
  参考文献：
  名称：

  SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

  摘要：

  Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5 -tetrahydro-1H-2-benzazepi ne and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.055
• 作为产物：
  描述：

  N-甲基-3,4-二甲氧基苄胺 在 氢溴酸 作用下， 反应 5.0h， 以100%的产率得到4-[(甲基氨基)甲基]-1,2-苯二酚氢溴酸盐(1:1)
  参考文献：
  名称：

  SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

  摘要：

  Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5 -tetrahydro-1H-2-benzazepi ne and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.055

文献信息

• SALTY TASTE ENHANCER
  申请人：AJINOMOTO CO., INC.

  公开号：US20140004243A1

  公开（公告）日：2014-01-02

  The present invention provides a compound having a salty taste enhance activity, and a salty taste enhancer containing the compound, and the like. The present invention relates to a salty taste enhancer for a food or drink, which contains a compound represented by the following formula: wherein each symbol is as defined in the specification, or an edible salt thereof.

  本发明提供了一种具有增强咸味活性的化合物，以及含有该化合物的增强咸味剂等。本发明涉及一种用于食品或饮料的增强咸味剂，其包含下式所示的化合物：其中每个符号如规范中所定义，或其可食用盐。
• SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure
  作者：Marı´a F. Dalence-Guzmán、Magnus Berglund、Staffan Skogvall、Olov Sterner

  DOI：10.1016/j.bmc.2007.11.055

  日期：2008.3

  Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5 -tetrahydro-1H-2-benzazepi ne and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. (C) 2007 Elsevier Ltd. All rights reserved.